1.0 0.8
Low-Intermediate rDRI (n = 119): 69% (61-79)
0.6
Supports robust GVL
0.2
0.4
High-V. High rDRI (n = 35): 56% (40-77)
P = 0.135
0.0
Progression-free Survival (%)
Midi dCBT: 3-year PFS by Disease Risk (rDRI, n = 154)
0
6
12
18 24 Months from dCBT
30
36
Politikos et al, 2018 ASBMT